NL-OMON51031
Recruiting
Not Applicable
Studying coagulation in COVID-19 using blood-vessel-on-chip technology. - COV-AGULATE
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 36
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Age \>18 yr or older
- •2\) Suspected SARS\-CoV\-2 infection
- •3\) Need for oxygen supplementation
- •4\) CRP\-level \* 50 mg/L
- •5\) D\-dimer level \*1\.0 mg/L
- •6\) Ability to provide written informed consent
Exclusion Criteria
- •1\) History of venous thromboembolism
- •2\) Use of anticoagulant therapy at inclusion
- •3\) Known hereditary or acquired thrombophilia
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Studying coagulation specific for COVID-19 using Blood-vessel-on-chip technology.COVID-19NL-OMON27363ZonMw24
Not yet recruiting
Not Applicable
A study of blood group in COVID-19 patients admitted at tertiary care hospital, AhmedabadCTRI/2021/01/030344Arpit Prajapati
Active, not recruiting
Phase 1
A Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 PandemicCoagulopathy of COVID-19 appears to afflict approximately 20% of patients with severe COVID-19 and is associated with need for critical care and death. COVID-19 coagulopathy is characterized by elevated D-dimer, an indicator of fibrin formation and clot lysis, and a mildly prolonged prothrombin time (PT), suggestive of coagulation consumptionTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2020-002190-10-IEniversity College Dublin24
Completed
Not Applicable
Blood Coagulation Abnormalities in COVID-19 (Corona Virus Disease-19) PatientsCovid19NCT04982263Sohag University125
Recruiting
Not Applicable
se of Convalescent Plasma in the treatment of COVID-19IRCT20200414047072N1Hilton Pharma Pvt. Ltd.357